Načítá se...
Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma
The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has...
Uloženo v:
| Vydáno v: | Adv Ther |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer Healthcare
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5331081/ https://ncbi.nlm.nih.gov/pubmed/28000166 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-016-0461-z |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|